See "Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)" on page 386-397.

Supplementary Table 1. Other Efficacy Endpoints in the Induction Study (Overall and East-Asian Population; Assessment at Week 8 and at Week 16)

At week 8	Overall population			East-Asian population		
	Placebo (n = 319)	UST 130 mg (n = 320)	UST 6 mg/kg (n = 322)	Placebo (n = 44)	UST 130 mg (n = 44)	UST 6 mg/kg (n = 45)
Histologic improvement,[a] n (%)	65 (21.9)	113 (37.9)	105 (35.6)	5 (11.6)	13 (30.2)	16 (36.4)
Symptomatic remission, n (%)	72 (22.6)	132 (41.3)	144 (44.7)	13 (29.5)	19 (43.2)	20 (44.4)
IBDQ, change from baseline to week 8,[b] median (IQR)	10.0 (–2.0; 34.0)	31.5 (7.5; 53.5)	31.0 (11.0; 56.0)	5.0 (–8.0; 15.0)	25.5 (8.0; 43.0)	26.0 (12.0; 50.0)
Efficacy by biologic failure status						
Prior biologic failure, n	161	164	166	28.0	28	29
Clinical remission, n (%)	2 (1.2)	19 (11.6)	21 (12.7)	0	2 (7.1)	3 (10.3)
Clinical response, n (%)	44 (27.3)	74 (45.1)	95 (57.2)	5 (17.9)	14 (50.0)	15 (51.7)
Biologic naïve or no biologic failure, n	158	156	156	16.0	16	16
Clinical remission, n (%)	15 (9.5)	31 (19.9)	29 (18.6)	0	3 (18.8)	2 (12.5)
Clinical response, n (%)	56 (35.4)	90 (57.7)	104 (66.7)	5 (31.3)	9 (56.3)	12 (75.0)
At week 16	**Placebo IV (I-0) → UST 6 mg/kg IV (I-8)**	**UST 130 mg IV (I-0) → UST 90 mg SC (I-8)**	**UST 6 mg/kg IV (I-0) → UST 90 mg SC (I-8)**	**Placebo IV (I-0) → UST 6 mg/kg IV (I-8)**	**UST 130 mg IV (I-0) → UST 90 mg SC (I-8)**	**UST 6 mg/kg IV (I-0) a → UST 90 mg SC (I-8)**
Placebo-responders/UST-nonresponders, n	184	132	101	28	17	12
Clinical remission, n (%)	24 (13.0)	13 (9.8)	9 (8.9)	4 (14.3)	0	1 (8.3)
Clinical response, n (%)	119 (64.7)	60 (45.5)	42 (41.6)	11 (39.3)	5 (29.4)	4 (33.3)
Endoscopic improvement, n (%)	40 (21.7)	23 (17.4)	16 (15.8)	9 (32.1)	6 (35.3)	4 (33.3)
Histo-endoscopic healing,[c] n (%)	30 (16.5)	13 (10.0)	15 (14.9)	5 (17.9)	3 (18.8)	2 (16.7)

[a]Excludes patients with an unevaluable biopsy (i.e., a biopsy that was collected, but could not be assessed due to sample preparation or technical errors) at week 8. Overall population: n = 297, 298 and 295 and East-Asian population: n = 43, 43 and 44 for placebo, UST 130 mg and UST 6 mg/kg, respectively.
[b]Patients who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the week 8 visit had their baseline value carried forward from the time of the event onward. Patients who had a missing IBDQ score at week 8 had their last value carried forward. Overall population: n = 317, 316 and 321 and East-Asian population: n = 44, 44 and 45 for Placebo, UST 130 mg and UST 6 mg/kg, respectively.
[c]Excludes patients whose mucosal healing status cannot be determined at week 16 due to with an unevaluable biopsy (i.e., a biopsy that was collected, but could not be assessed due to sample preparation or technical errors). Note that patients who had an unevaluable biopsy at week 16, but who did not achieve endoscopic healing, were considered not to have mucosal healing. Overall population: n = 182, 130 and 101 and East-Asian population: n = 28, 16 and 12 for placebo, UST 130 mg and UST 6 mg/kg, respectively.
UST, ustekinumab; IBDQ, Inflammatory Bowel Disease Questionnaire; IQR, interquartile range; IV, intravenous; SC, subcutaneous; I-0, induction (week 0); I-8, induction (week 8).